当前位置： SCI文献检索 > AMERICAN JOURNAL OF OPHTHALMOLOGY期刊下所有文献 > Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.

Abstract：

PURPOSE:To evaluate the effects of a dexamethasone intravitreous drug delivery system (dexamethasone DDS) in patients with persistent macular edema (ME) resulting from uveitis or Irvine-Gass syndrome. DESIGN:Randomized, prospective, single-masked, controlled trial. METHODS:Three hundred and fifteen patients with persistent (>or= 90 days) ME were randomized in a multicenter study to surgical placement of 350 or 700 microg dexamethasone DDS or observation. This study evaluated the subset of patients with uveitis or Irvine-Gass syndrome (n = 41). The primary outcome measure was the proportion of patients achieving a 10-letter or more improvement in best-corrected visual acuity (BCVA) at day 90. Change in fluorescein angiographic leakage and safety also were evaluated. RESULTS:At day 90, a 10-letter or more BCVA improvement was seen in 41.7% (5/12) of patients in the 350-microg group, in 53.8% (7/13) of patients in the 700-microg group, and in 14.3% (2/14) of patients in the observation group (P = .029 vs the 700-microg group). Improvement in visual acuity persisted to day 180. A 15-letter or more improvement was achieved in 53.8% (7/13) of 700-microg patients vs 7.1% (1/14) of observed patients (P = .008). There were significantly greater reductions in fluorescein leakage in treated patients than in observed patients. Dexamethasone DDS was well tolerated. Throughout the study, an increase in intraocular pressure of 10 mm Hg or more was seen in 5 of 13 patients in the 700-microg group, in 1 of 12 patients in the 350-microg group, and in no patients in the observation group. There were no reports of endophthalmitis. CONCLUSIONS:In patients with persistent ME resulting from uveitis or Irvine-Gass syndrome, 700-microg dexamethasone DDS was well tolerated and produced statistically significant improvements in visual acuity and fluorescein leakage.

journal_name

Am J Ophthalmol

journal_title

American journal of ophthalmology

authors

Williams GA,Haller JA,Kuppermann BD,Blumenkranz MS,Weinberg DV,Chou C,Whitcup SM,Dexamethasone DDS Phase II Study Group.

doi

10.1016/j.ajo.2008.12.033

subject

Has Abstract

pub_date

2009-06-01 00:00:00

pages

1048-54, 1054.e1-2

issue

eissn

0002-9394

issn

1879-1891

pii

S0002-9394(09)00002-6

journal_volume

147

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.